BR112015009602A2 - análogos quiméricos de somatostatina-dopamina - Google Patents

análogos quiméricos de somatostatina-dopamina

Info

Publication number
BR112015009602A2
BR112015009602A2 BR112015009602A BR112015009602A BR112015009602A2 BR 112015009602 A2 BR112015009602 A2 BR 112015009602A2 BR 112015009602 A BR112015009602 A BR 112015009602A BR 112015009602 A BR112015009602 A BR 112015009602A BR 112015009602 A2 BR112015009602 A2 BR 112015009602A2
Authority
BR
Brazil
Prior art keywords
somatostatin
dopamine chimeric
chimeric analogs
dopamine
analogs
Prior art date
Application number
BR112015009602A
Other languages
English (en)
Inventor
Hyuk Kim Sun
Shen Yeelana
Xin Dong Zheng
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of BR112015009602A2 publication Critical patent/BR112015009602A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/52—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)

Abstract

resumo “análogos quiméricos de somatostatina-dopamina” a presente invenção refere-se a novos análogos quiméricos de somatostatina­dopamina e suas utilizações terapêuticas para a inibição, prevenção e / ou tratamento de neoplasia, tumores neuroendócrinos, doença / síndrome de cushing, e outras condições.
BR112015009602A 2012-11-01 2013-10-31 análogos quiméricos de somatostatina-dopamina BR112015009602A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261721372P 2012-11-01 2012-11-01
PCT/US2013/067661 WO2014070971A2 (en) 2012-11-01 2013-10-31 Somatostatin-dopamine chimeric analogs

Publications (1)

Publication Number Publication Date
BR112015009602A2 true BR112015009602A2 (pt) 2017-11-14

Family

ID=50547875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009602A BR112015009602A2 (pt) 2012-11-01 2013-10-31 análogos quiméricos de somatostatina-dopamina

Country Status (18)

Country Link
US (3) US9731027B2 (pt)
EP (1) EP2914280B1 (pt)
JP (2) JP5908184B2 (pt)
KR (1) KR101770231B1 (pt)
CN (1) CN104768570B (pt)
AR (1) AR093327A1 (pt)
AU (1) AU2013337851A1 (pt)
BR (1) BR112015009602A2 (pt)
CA (1) CA2888765A1 (pt)
EA (1) EA038157B1 (pt)
ES (1) ES2663956T3 (pt)
HK (1) HK1213485A1 (pt)
IL (1) IL238080A0 (pt)
MX (1) MX2015005531A (pt)
SA (1) SA515360377B1 (pt)
SG (1) SG11201502486RA (pt)
TW (1) TWI523863B (pt)
WO (1) WO2014070971A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015120570A (ru) * 2012-11-01 2016-12-20 Ипсен Фарма С.А.С. Аналоги соматостатина и их димеры
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
CN105820215A (zh) * 2016-05-09 2016-08-03 中国人民解放军第二军医大学 一种高效合成Stylissatin A天然环七肽的制备方法
EP3850954A4 (en) * 2018-09-14 2022-06-08 Megumi Tanaka ANTI-AGING AGENT AND ANTI-AGING PROCESS

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2619488A (en) 1952-11-25 Method of preparing d
US2589978A (en) 1952-03-18 Lysergyl and isolysergyl glycines
AT258479B (de) 1961-05-29 1967-11-27 Farmaceutici Italia Verfahren zur Herstellung von neuen Verbindungen aus der Klasse des D-6-Methyl- (und -1,6-Dimethyl)-8-amino-methyl-ergolins I
FR98F (pt) 1961-05-29
US3966941A (en) 1970-09-23 1976-06-29 Spofa United Pharmaceutical Works Composition for preventing lactation or pregnancy in mammals and the method for using the same
US3901894A (en) 1974-06-06 1975-08-26 Lilly Co Eli 8-thiomethylergolines
HU172479B (hu) 1976-03-09 1978-09-28 Gyogyszerkutato Intezet Sposob poluchenija novykh soedinenij s ehrgolenovymi i
US4166182A (en) 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
DD140044A1 (de) 1978-11-08 1980-02-06 Guenter Losse Verfahren zur herstellung von lysergyl-enkephalin-derivaten
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB2112382B (en) 1981-11-06 1985-03-06 Erba Farmitalia Ergoline derivatives
CH652720A5 (en) 1983-02-16 1985-11-29 Sandoz Ag Ergoline derivatives, their preparation and use
PH21123A (en) 1983-04-28 1987-07-27 Erba Farmitalia Ergoline derivatives
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
DE3845000C2 (de) 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
GB8813339D0 (en) 1988-06-06 1988-07-13 Sandoz Ltd Improvements in/relating to organic compounds
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
US5411966A (en) 1990-01-15 1995-05-02 Schering Aktiengesellschaft 2, 13-disubstituted ergolines, their production and use in pharmaceutical agents
ATE131167T1 (de) 1990-01-25 1995-12-15 Pharmacia Spa Verfahren zur herstellung von ergolinderivaten.
US5043341A (en) 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
WO1992000986A1 (en) 1990-07-10 1992-01-23 Neurogenetic Corporation Nucleic acid sequences encoding a human dopamine d1 receptor
DK0720621T3 (da) 1992-01-14 2001-08-06 Diatide Inc Radiomærkede somatostation-afledte peptider til billeddannende og terapeutiske anvendelser
EP0628042B1 (en) 1992-12-24 2001-08-16 PHARMACIA & UPJOHN S.p.A. Serotoninergic ergoline derivatives
AU692435B2 (en) 1993-01-21 1998-06-11 United States Of America, As Represented By The Secretary Of Agriculture, The Vaccines and methods for preventing and treating fescue toxicosis in herbivo res
JPH09510182A (ja) 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
AU2582197A (en) 1996-03-15 1997-10-01 Start Technology Partnership Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
AU3215597A (en) * 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5925618A (en) 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
GB9711043D0 (en) 1997-05-29 1997-07-23 Ciba Geigy Ag Organic compounds
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
DE19832191A1 (de) 1998-07-17 2000-01-27 Knoell Hans Forschung Ev Neuartige Ergolinamin-Derivate und ihre Verwendung
WO2000004916A1 (en) 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
US6465613B1 (en) * 1998-11-19 2002-10-15 Tulane University Hydrophilic somatostatin analogs
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1198478B1 (en) 2000-07-31 2005-03-23 Dabur Research Foundation Somatostatin analogs and their use for the treatment of cancer
WO2002085902A1 (en) 2001-04-16 2002-10-31 Finetech Laboratories Ltd. Process and intermediates for production of cabergoline and related compounds
KR100754917B1 (ko) 2001-06-08 2007-09-04 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 소마토스타틴-도파민 키메라 유사체
EP1283216A1 (en) 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
KR100593348B1 (ko) 2001-08-23 2006-06-26 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드-1 유사체
GB0300095D0 (en) 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AU2004220104A1 (en) * 2003-03-10 2004-09-23 Biogen Idec Inc. Thiol-mediated drug attachment to targeting peptides
MXPA05010868A (es) * 2003-04-11 2005-11-25 Conseils De Rech S Et D Aplica Analogos quimericos de somatostatina-dopamina.
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
CA2550695A1 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 pharmaceutical compositions
RU2390331C2 (ru) 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
GB0412866D0 (en) 2004-06-09 2004-07-14 Novartis Ag Organic compounds
US7402652B2 (en) 2004-09-14 2008-07-22 Miller Landon C G Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders
KR101364374B1 (ko) 2005-03-14 2014-02-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 생활성 ｆｕｓ1 펩티드 및 나노입자-폴리펩티드 복합체
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2007127158A2 (en) 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
FR2902101B1 (fr) 2006-06-12 2012-12-28 Scras Peptides a activite anti-proliferative
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2464039C2 (ru) * 2008-05-14 2012-10-20 Ипсен Фарма С.А.С. Фармацевтические композиции конъюгатов соматостатин-дофамин
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
UA102432C2 (ru) 2009-02-20 2013-07-10 Іпсен Фарма С.А.С. Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
WO2011104627A1 (en) 2010-02-24 2011-09-01 Ipsen Pharma S.A.S. Metabolites of dop2-d-lys(dop2)-cyclo[cys-tyr-d-trp-lys-abu-cys]-thr-nh2
ES2579941T3 (es) 2010-03-15 2016-08-17 Ipsen Pharma S.A.S. Composiciones farmacéuticas de ligandos del receptor de secretagogos de la hormona del crecimiento
RU2015120570A (ru) 2012-11-01 2016-12-20 Ипсен Фарма С.А.С. Аналоги соматостатина и их димеры
TWI523863B (zh) * 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物

Also Published As

Publication number Publication date
SA515360377B1 (ar) 2016-10-10
US20150290330A1 (en) 2015-10-15
SG11201502486RA (en) 2015-04-29
HK1213485A1 (zh) 2016-07-08
EP2914280B1 (en) 2018-01-03
AU2013337851A1 (en) 2015-04-23
EP2914280A2 (en) 2015-09-09
CN104768570B (zh) 2017-12-15
WO2014070971A2 (en) 2014-05-08
US20150148522A1 (en) 2015-05-28
JP2015535286A (ja) 2015-12-10
US9603942B2 (en) 2017-03-28
US20140121354A1 (en) 2014-05-01
KR101770231B1 (ko) 2017-08-23
IL238080A0 (en) 2015-05-31
JP2016166206A (ja) 2016-09-15
KR20150076195A (ko) 2015-07-06
TW201422636A (zh) 2014-06-16
CN104768570A (zh) 2015-07-08
MX2015005531A (es) 2015-07-17
ES2663956T3 (es) 2018-04-17
TWI523863B (zh) 2016-03-01
WO2014070971A3 (en) 2014-07-03
US9731027B2 (en) 2017-08-15
JP5908184B2 (ja) 2016-04-26
EP2914280A4 (en) 2016-04-27
AR093327A1 (es) 2015-06-03
EA038157B1 (ru) 2021-07-15
US8952128B2 (en) 2015-02-10
CA2888765A1 (en) 2014-05-08
EA201590841A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
WO2015095811A3 (en) Combination therapy with neoantigen vaccine
BR112014003477A2 (pt) composições imunoterapêuticas de levedura-muc1 e usos das mesmas
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
BR112015009602A2 (pt) análogos quiméricos de somatostatina-dopamina
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2016008968A (es) Compuestos organicos.
PH12015502703A1 (en) Pharmaceutical compositions
EA201690938A1 (ru) Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
WO2013030670A3 (en) Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers
UA113065C2 (xx) Композиція для нанесення на шкіру та її застосування
IN2014DN10683A (pt)
EA201400970A1 (ru) Новые композиции для лечения амиотрофического бокового склероза
GB201206984D0 (en) New therapeutic use
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B350 Update of information on the portal [chapter 15.35 patent gazette]